PTHS
Pelthos Therapeutics Inc.Company Information
- Company Name
- Pelthos Therapeutics Inc.
- CIK
- CIK0001919246
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- PTHS: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- PTHS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-11
- Last sale
- 2026-07-02
- Shares purchased (TTM)
- 35,948
- Shares sold (TTM)
- 16,655
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,323,157
- Shares outstanding
- 3,539,464
- Ownership
- 37.38%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -15.89%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | - | - | - | 14 | 0 | 0 | 1 | 1 | 2 | 4 | 0 | ||||||
Assets | |||||||||||||||||
| Operating Lease Liability | - | 3 | - | 3 | - | - | - | - | - | - | - | ||||||
| Deferred Revenue | - | - | - | 2 | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | 13 | - | - | - | - | - | - | - | ||||||
| Nonrelated Party | 2 | - | 0 | - | - | - | 2 | - | - | - | - | ||||||
Assets Current | |||||||||||||||||
| Related Party | 2 | - | 0 | - | - | - | 2 | - | - | - | - | ||||||
| Series A Preferred Stock | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - | ||||||
| Series C Preferred Stock | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 24 | 32 | 18 | - | 0 | 0 | 1 | - | - | - | - | ||||||
| Cash And Due From Banks | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Accounts And Other Receivables Net Current | - | - | - | 8 | - | - | - | - | - | - | - | ||||||
| Deferred Offering Costs | - | - | 1 | - | 1 | 1 | 1 | 1 | - | - | - | ||||||
| Accounts Receivable Net Current | 14 | 12 | 9 | - | - | - | 0 | - | - | - | - | ||||||
| Inventory Net | 21 | 23 | 24 | 24 | - | - | 0 | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | 5 | 3 | 2 | 1 | 1 | 2 | 5 | ||||||
| Assets Current | 63 | 70 | 53 | 50 | 1 | 1 | 1 | 2 | 3 | 4 | 0 | ||||||
| Property Plant And Equipment Net | 9 | 9 | 10 | 10 | - | - | 0 | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | - | - | 0 | - | - | - | - | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | 33 | - | - | - | - | - | - | - | ||||||
| Finite Lived Intangible Assets Net | 37 | 38 | 39 | - | - | - | 0 | - | - | - | - | ||||||
| Goodwill | 25 | 25 | 25 | 31 | - | - | 0 | - | - | - | - | ||||||
| Assets | 137 | 145 | 130 | 126 | 1 | 1 | 1 | 2 | 3 | 4 | 0 | ||||||
| Accounts Payable Current | 6 | 6 | 3 | 6 | - | - | 2 | - | - | - | - | ||||||
| Accrued Liabilities Current | 21 | 13 | 15 | 12 | 0 | - | 0 | 0 | 0 | 0 | 1 | ||||||
| Bridge Loan | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Other Loans Payable | - | - | - | - | 2 | 2 | 2 | 2 | 1 | - | 0 | ||||||
| Loans Payable | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | 1 | ||||||
| Asset Acquisition Contingent Consideration Liability Current | 1 | 1 | 2 | - | - | - | 0 | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | - | - | 0 | - | - | - | - | ||||||
| Deferred Revenue Current | - | - | - | 1 | - | - | - | - | - | - | - | ||||||
| Contract With Customer Liability Current | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | ||||||
| Other Liabilities Current | - | 3 | 4 | 6 | - | - | 0 | - | - | - | - | ||||||
| Liabilities Current | 32 | 25 | 26 | 25 | 7 | 5 | 4 | 4 | 3 | 3 | 7 | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 3 | - | - | - | 0 | - | - | - | - | ||||||
| Contract With Customer Liability Noncurrent | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | ||||||
| Convertible Debt Noncurrent | 43 | 39 | 31 | - | - | - | 0 | - | - | - | - | ||||||
| Secured Long Term Debt | 27 | 26 | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | - | 32 | 30 | 26 | - | - | 0 | - | - | - | - | ||||||
| Liabilities | 139 | 126 | 92 | 68 | 7 | 5 | 4 | 4 | 3 | 3 | 7 | ||||||
Stockholders Equity | |||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 110 | 107 | 104 | 101 | 20 | 19 | 19 | 18 | 18 | 17 | 7 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 2 | 2 | - | - | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -113 | -90 | -65 | -43 | -27 | -23 | -21 | -20 | -18 | -16 | -14 | ||||||
| Stockholders Equity | -2 | 19 | 39 | 58 | -6 | -4 | -3 | -1 | -0 | 1 | -6 | ||||||
| Liabilities And Stockholders Equity | 137 | 145 | 130 | 126 | 1 | 1 | 1 | 2 | 3 | 4 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 4 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Shares Outstanding | 4 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPelthos Therapeutics Inc. (PTHS) — SEC Financial Statements & Analysis
Pelthos Therapeutics Inc. (PTHS) is a biological products, (no diagnostic substances) company, incorporated in NV. Pelthos Therapeutics Inc. trades on NYSE as: PTHS. Pelthos Therapeutics Inc. (PTHS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Pelthos Therapeutics Inc. carries a market cap of $100.03M, a P/E ratio of -1.16x, a P/B ratio of -66.64x, a P/S ratio of 2.31x, an enterprise value of $145.75M, and an EV/EBITDA multiple of -2.61x. On profitability, it posts a gross margin of 78.59%, an operating margin of -133.42%, a net margin of -199.50%, a Return on Equity (ROE) of 2160.88%, a Return on Assets (ROA) of -125.04%, and a Return on Invested Capital (ROIC) of -276.26%. Per share, it reports EPS of $-24.41, diluted EPS of $-24.41, free cash flow per share of $-13.72, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 855.87% year-over-year and EPS growth of 76.06% year-over-year. On the balance sheet, it maintains a current ratio of 1.98x, a quick ratio of 1.22x, working capital of $31.40M, a debt-to-equity ratio of -92.51x, a debt ratio of 1.01, an interest coverage ratio of -9.49x, free cash flow of $-48.58M (TTM), and net debt of $45.72M. Figures sourced from SEC EDGAR.
- Market Cap
- $100.03M
- P/E TTM
- -1.16x
- EPS TTM
- $-24.41
- P/B TTM
- -66.64x
- ROE TTM
- 2160.88%
- ROA TTM
- -125.04%
- Debt To Equity
- -92.51x
- Free Cash Flow TTM
- $-48.58M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Pelthos Therapeutics Inc. in?
Pelthos Therapeutics Inc. (PTHS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does PTHS trade on?
Pelthos Therapeutics Inc. (PTHS) trades on the NYSE.
Where is Pelthos Therapeutics Inc. incorporated?
Pelthos Therapeutics Inc. is incorporated in NV.
When was Pelthos Therapeutics Inc. (PTHS)'s most recent SEC filing?
Pelthos Therapeutics Inc. (PTHS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is PTHS's market cap?
Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $100.03M as of 2026-06-30.
What is PTHS's EPS (earnings per share)?
Pelthos Therapeutics Inc. (PTHS)'s trailing twelve month EPS is $-24.41 as of 2026-06-30.
What is PTHS's ROE (return on equity)?
Pelthos Therapeutics Inc. (PTHS)'s trailing twelve month Return on Equity (ROE) is 2160.88% as of 2026-06-30.
What is PTHS's ROA (return on assets)?
Pelthos Therapeutics Inc. (PTHS)'s trailing twelve month Return on Assets (ROA) is -125.04% as of 2026-06-30.
What is PTHS's ROIC (return on invested capital)?
Pelthos Therapeutics Inc. (PTHS)'s trailing twelve month Return on Invested Capital (ROIC) is -276.26% as of 2026-06-30.
What is PTHS's EV/EBITDA?
Pelthos Therapeutics Inc. (PTHS)'s trailing twelve month EV/EBITDA is -2.61x as of 2026-06-30.